CE7R

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCE7R
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionVascular cell adhesion molecule 1 modulatorsT-cell receptor modulatorsGene transference +[4] 
TargetsVascular cell adhesion molecule 1T-cell receptor
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Active IndicationsN/A
Inactive IndicationsNeuroblastoma

Other Information

ATC CodeN/A
Related LinksN/A